EANS-Adhoc: SYGNIS Pharma AG
SYGNIS announces intended changes in the Supervisory Board

  ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro
  adhoc with the aim of a Europe-wide distribution. The issuer is solely
  responsible for the content of this announcement.
Company Information


SYGNIS announces intended changes in the Supervisory Board

Heidelberg, 6 September 2012 - SYGNIS Pharma AG (Frankfurt: LIOK; ISIN
DE000A1E9B74; Prime Standard) shall, as already announced on 18 July, 2012,
acquire 100% ownership of X-Pol Biotech, S.L., by way of capital increase
against contribution in kind and therefore X-Pol Biotech, S.L., will become a
100% subsidiary of SYGNIS Pharma AG. According to the business valuation as of
today and subject to a corresponding resolution of the shareholders of SYGNIS
Pharma AG, the existing shareholders of X-Pol Biotech, S.L., will hold 77.5% of
all shares in SYGNIS Pharma AG after the proposed transaction. By an approving
resolution on the Shareholders' Meeting regarding the therefore necessary
capital increase against contribution in kind the Shareholders' Meeting will
create the fundamental conditions for a significant change of the shareholder
structure of SYGNIS Pharma AG.

In the event the Shareholders' Meeting approves the planned capital increase of
the Company against contribution in kind, the current Members of the
Supervisory Board Prof. Dr. Friedrich von Bohlen und Halbach, Prof. Dr.
Christof Hettich, Prof. Dr. Werner Hacke, Prof. Dr. Wolfgang Hartwig, Prof. Dr.
Andrea Pfeifer and Dr. Wolf-Dieter Starp have notified the Management Board of
SYGNIS Pharma AG subsequently to their Supervisory Board Meeting of 6
September, 2012, about their intention to resign from office with effect of the
end of the Shareholders' Meeting approving the capital increase against
contribution in kind. By intending to resign from office the needed
reorientation of SYGNIS Pharma AG shall be supported. Prof. Dr. Friedrich von
Bohlen und Halbach as well as Dr. Wolf-Dieter Starp intend to seek for re-
election into the Supervisory Board.

For further information please contact:

|Peter Willinger                         |
|Co-CEO/CFO                              |
|Tel: +49 (0) 6221-454 836               |
|Email:           |

### Disclaimer

This publication is intended for information only  and  constitutes  neither  an
offer to sell nor an invitation to buy securities. Some statements  included  in
this press release, relating neither  to  proven  financial  results  nor  other
historical data, should be viewed as forward-looking, i.e.  not  definite.  Such
statements are mainly predictions of future results,  trends,  plans  or  goals.
These statements should not be considered to be  total  guarantees  since  given
their  very  nature  they  are  subject  to  known   and   unknown   risks   and
imponderability and can be affected by other factors as a consequence  of  which
the actual results, plans and goals of SYGNIS  Pharma  AG  may  deviate  greatly
from the established  conclusions  or  implied  predictions  contained  in  such
statements. SYGNIS does  not  undertake  to  publicly  update  or  revise  these
statements in the light of new information or future results or  for  any  other

Further inquiry note:
Marc Risch
Telefon: +49 (6221) 454 - 737

end of announcement                               euro adhoc 

issuer:      SYGNIS Pharma AG
             Im Neuenheimer Feld 515
             D-69120 Heidelberg
phone:       +49 (0)6221 454-6
FAX:         +49 (0)6221 454-777
sector:      Biotechnology
ISIN:        DE000A1E9B74
indexes:     CDAX, Prime All Share
stockmarkets: free trade: Hannover, Berlin, München, Hamburg, Düsseldorf,
             Stuttgart, regulated dealing/prime standard: Frankfurt 
language:   English

Weitere Meldungen: SYGNIS AG

Das könnte Sie auch interessieren: